Logo

Mylan and Biocon Launch Ogivri (biosimilar- trastuzumab) in Australia

Share this

Mylan and Biocon Launch Ogivri (biosimilar- trastuzumab) in Australia

Shots:

  • Ogivri is the first biosimilar to Herceptin (trastuzumab) to be approved and launched in Australia for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer and will be available on the Pharmaceutical Benefits Scheme
  • The TGA’s approval of Ogivri is based on data which demonstrated bio-similarity to Herceptin with no clinically meaningful differences in efficacy- safety- purity and potency. The HERITAGE study resulted in bio-similarity in terms of reduction in tumor size @24 wks. & OS @48 wks.
  •  Ogivri is a biosimilar of Roche’s Herceptin and has received FDA’s approval in Dec’2017 for HER2-overexpressing breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma

Click here to­ read full press release/ article | Ref: Biocon | Image: Patch


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions